MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.21
+1.06
+3.02%
After Hours: 36.21 0 0.00% 16:34 05/20 EDT
OPEN
36.01
PREV CLOSE
35.15
HIGH
36.64
LOW
33.90
VOLUME
735.59K
TURNOVER
--
52 WEEK HIGH
93.66
52 WEEK LOW
27.87
MARKET CAP
3.83B
P/E (TTM)
-33.3548
1D
5D
1M
3M
1Y
5Y
Catalyst Watch: JPMorgan event, Best Buy earnings and McDonald's drama
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 1d ago
ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT
Benzinga · 5d ago
--B. Riley Lowers Arrowhead Pharmaceuticals' PT to $82 from $106 to Account for Higher Research & Development Spend, Increased Cost of Capital; Keeps Buy Rating
MT Newswires · 05/13 09:56
Arrowhead Pharma down 12% despite quarterly beats, swing to net gain
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is down 12% in Wednesday afternoon trading despite reporting Q1 2022 results after the closing bell Tuesday that beat on the top and bottom lines. The company swung to
Seekingalpha · 05/11 18:12
--Piper Sandler Lowers Arrowhead Pharmaceuticals Price Target to $72 From $89, Maintains Overweight Rating
MT Newswires · 05/11 12:13
--Chardan Lowers Arrowhead Pharmaceuticals Price Target to $80 From $94, Maintains Buy Rating
MT Newswires · 05/11 11:19
--Baird Upgrades Arrowhead Pharmaceuticals to Outperform From Neutral, Cuts Price Target to $60 From $71
MT Newswires · 05/11 07:33
Arrowhead Pharmaceuticals: Q2 Earnings Insights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/10 22:19
More
No Data
Learn about the latest financial forecast of ARWR. Analyze the recent business situations of Arrowhead Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

18.18%Strong Buy
72.73%Buy
9.09%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ARWR stock price target is 80.08 with a high estimate of 100.00 and a low estimate of 35.00.
High100.00
Average80.08
Low35.00
Current 36.21
EPS
Actual
Estimate
-0.39-0.160.060.29
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 438
Institutional Holdings: 84.80M
% Owned: 80.20%
Shares Outstanding: 105.74M
TypeInstitutionsShares
Increased
104
3.03M
New
48
1.44M
Decreased
110
2.56M
Sold Out
33
405.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Douglass Given
Chief Executive Officer/President/Director
Christopher Anzalone
Chief Financial Officer
Kenneth Myszkowski
Senior Vice President
James Hamilton
Chief Compliance Officer/General Counsel/Secretary
Patrick O'Brien
Other
Javier San Martin
Lead Director/Independent Director
Michael Perry
Independent Director
Marianne De Backer
Independent Director
Mauro Ferrari
Independent Director
Adeoye Olukotun
Independent Director
Victoria Vakiener
Independent Director
William Waddill
No Data
No Data
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.